Ischemic Preconditioning Reveals that GLT1/EAAT2 Glutamate Transporter is a Novel PPARγ Target Gene Involved in Neuroprotection
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Excessive levels of extracellular glutamate in the nervous system are excitotoxic and lead to neuronal death. Glutamate transport, mainly by glutamate transporter GLT1/EAAT2, is the only mechanism for maintaining extracellular glutamate concentrations below excitotoxic levels in the central nervous system. We recently showed that neuroprotection after experimental ischemic preconditioning (IPC) involves, at least partly, the upregulation of the GLT1/EAAT2 glutamate transporter in astrocytes, but the mechanisms were unknown. Thus, we decided to explore whether activation of the nuclear receptor peroxisome proliferator-activated receptor (PPAR)γ, known for its antidiabetic and antiinflammatory properties, is involved in glutamate transport. First, we found that the PPARγ antagonist T0070907 inhibits both IPC-induced tolerance and reduction of glutamate release after lethal oxygen-glucose deprivation (OGD) (70.1% ± 3.4% versus 97.7% ± 5.2% of OGD-induced lactate dehydrogenase (LDH) release and 61.8% ± 5.9% versus 85.9% ± 7.9% of OGD-induced glutamate release in IPC and IPC + T0070907 1 μmol/L, respectively, n = 6 to 12, P < 0.05), as well as IPC-induced astrocytic GLT-1 overexpression. IPC also caused an increase in nuclear PPARγ transcriptional activity in neurons and astrocytes (122.1% ± 8.1% and 158.6% ± 22.6% of control PPARγ transcriptional activity, n = 6, P < 0.05). Second, the PPARγ agonist rosiglitazone increased both GLT-1/EAAT2 mRNA and protein expression and [3 H]glutamate uptake, and reduced OGD-induced cell death and glutamate release (76.3% ± 7.9% and 65.5% ± 15.1% of OGD-induced LDH and glutamate release in rosiglitazone 1 μmol/l, respectively, n = 6 to 12, P < 0.05). Finally, we have identified six putative PPAR response elements (PPREs) in the GLT1/EAAT2 promoter and, consistently, rosiglitazone increased fourfold GLT1/EAAT2 promoter activity. All these data show that the GLT1/EAAT2 glutamate transporter is a target gene of PPARγ leading to neuroprotection by increasing glutamate uptake.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Kliewer, S. A., Sundseth, S. S., Jones, S. A., Brown, P. J., Wisely, G. B., Koble, C. S., Devchand, P., Wahli, W., Willson, T. M., Lenhard, J. M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4318 · Cited by 2,164 · cited 1×
“…prostaglandin 15dPGJ2 (Forman et al, 1995; Kliewer et al, 1995), fatty acids including oleic, linoleic, linolenic, and arachidonic acids (Kliewer et al, 1997), as well as nitrolinoleic acid (Schopfer et al, 2005) and epoxyeicosatrienoic acids (Liu et al, 2005), oxidized alkyl…”
BackgroundKliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
Rothstein, J. D., Patel, S., Regan, M. R., Haenggeli, C., Huang, Y. H., Bergles, D. E., Jin, L., Dykes Hoberg, M., Vidensky, S., Chung, D. S., et al. (2005) · Nature · doi:10.1038/nature03180 · Cited by 1,518 · cited 1×
“…are no currently approved pharmacologic treatments aimed to upregulate GLT-1/EAAT2 transporter and, experimentally, only a few drugs (estrogen, b-lactam antibiotics, and glucocorticoids) are known to increase GLT-1/EAAT2 expression (Pawlak et al, 2005; Rothstein et al, 2005; Zschocke et al, 2005).”
BackgroundMitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone.
Wilson-Fritch, L., Nicoloro, S., Chouinard, M., Lazar, M. A., Chui, P. C., Leszyk, J., Straubhaar, J., Czech, M. P., & Corvera, S. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21752 · Cited by 616 · cited 1×
“The involvement of other effects of rosiglitazone in neuroprotection, such as an increased mitochondrial biogenesis as recently described in other systems (Wilson-Fritch et al, 2004), remains to be investigated.”
BackgroundCombs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
LI, S., MALLORY, M., ALFORD, M., TANAKA, S., & MASLIAH, E. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199708000-00008 · Cited by 343
Glutamate Transporters in Neurologic Disease
Maragakis, N. J., & Rothstein, J. D. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.365 · Cited by 324 · cited 7×
“…by specific transporters is the primary and only mechanism for maintaining extracellular glutamate concentrations below excitotoxic levels in the central nervous system (CNS) (Takahashi et al, 1997; Seal and Amara, 1999; Gegelashvili et al, 2001; Danbolt, 2001; Maragakis and Rothstein, 2001).”
BackgroundInfluentialLee, G., Elwood, F., McNally, J., Weiszmann, J., Lindstrom, M., Amaral, K., Nakamura, M., Miao, S., Cao, P., Learned, R. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200743200 · Cited by 319 · cited 16×
“In addition, T0070907 (0.1 to 1mmol/L) reversed the inhibitory effect of IPC on OGD-induced glutamate release (Figure 1B).”
BackgroundMethodInfluential
Cited by
Sheldon, A. L., & Robinson, M. B. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.03.012 · Cited by 594
Dirnagl, U., Becker, K., & Meisel, A. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70054-7 · Cited by 587
Pajarillo, E., Rizor, A., Lee, J., Aschner, M., & Lee, E. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.03.002 · Cited by 478
Ischemia-Triggered Glutamate Excitotoxicity From the Perspective of Glial Cells
Belov Kirdajova, D., Kriska, J., Tureckova, J., & Anderova, M. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00051 · Cited by 428
Kim, K., Lee, S., Kegelman, T. P., Su, Z., Das, S. K., Dash, R., Dasgupta, S., Barral, P. M., Hedvat, M., Diaz, P., et al. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22609 · Cited by 395
Metadata
- Authors
- Romera, C., Hurtado, O., Mallolas, J., Pereira, M. P., Morales, J. R., Romera, A., Serena, J., Vivancos, J., Nombela, F., Lorenzo, P., Lizasoain, I., & Moro, M. A.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2007-07
- Volume
- 27
- Issue
- 7
- Pages
- 1327-1338
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2011632313
- Cited by
- 133
- References
- 9
- FWCI
- 4.23
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ischemic Preconditioning Reveals that GLT1/EAAT2 Glutamate Transporter is a Novel PPARγ Target Gene Involved in Neuroprotection. https://app.cochat.ai/papers/10.1038/sj.jcbfm.9600438
- The paper
- Romera, C., Hurtado, O., Mallolas, J., Pereira, M. P., Morales, J. R., Romera, A., Serena, J., Vivancos, J., Nombela, F., Lorenzo, P., Lizasoain, I., & Moro, M. A. (2007). Ischemic Preconditioning Reveals that GLT1/EAAT2 Glutamate Transporter is a Novel PPARγ Target Gene Involved in Neuroprotection. Journal of Cerebral Blood Flow & Metabolism. https://doi.org/10.1038/sj.jcbfm.9600438
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.